{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:22:04Z","timestamp":1789928524107,"version":"4.0.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,14]]},"DOI":"10.1093\/eurheartj\/ehs166","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T11:32:36Z","timestamp":1340796756000},"page":"802-808","source":"Crossref","is-referenced-by-count":83,"title":["Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis"],"prefix":"10.1093","volume":"34","author":[{"given":"Zaheer","family":"Yousef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Escoubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Monserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Namdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,6,26]]},"reference":[{"key":"key\n\t\t\t\t20170626080130_EHS166C1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626080130_EHS166C2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"key\n\t\t\t\t20170626080130_EHS166C3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2009.02.075","article-title":"Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy","volume":"54","author":"Bos","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080130_EHS166C4","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","article-title":"Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention","volume":"113","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080130_EHS166C5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080130_EHS166C6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080130_EHS166C7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626080130_EHS166C8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20170626080130_EHS166C9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2009.08.002","article-title":"Cardiac challenges in patients with Fabry disease","volume":"141","author":"Weidemann","year":"2010","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170626080130_EHS166C10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170626080130_EHS166C11","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170626080130_EHS166C12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080130_EHS166C13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"key\n\t\t\t\t20170626080130_EHS166C14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J Med Genet"},{"key":"key\n\t\t\t\t20170626080130_EHS166C15","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.amjmed.2009.12.022","article-title":"Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge","volume":"123","author":"Weidemann","year":"2010","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170626080130_EHS166C16","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080130_EHS166C17","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/eurheartj\/ehm456","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology","volume":"28","author":"Cooper","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080130_EHS166C18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12265-009-9139-0","article-title":"A new era in clinical genetic testing for hypertrophic cardiomyopathy","volume":"2","author":"Wheeler","year":"2009","journal-title":"J Cardiovasc Transl Res"},{"key":"key\n\t\t\t\t20170626080130_EHS166C19","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review of available evidence","volume":"69","author":"Schaefer","year":"2009","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170626080130_EHS166C20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/34\/11\/802\/17894458\/ehs166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T22:53:12Z","timestamp":1503442392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehs166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,26]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,6,26]]},"published-print":{"date-parts":[[2013,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehs166","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,26]]}}}